Last updated: February 20, 2026
What is the Content of Patent DK3221313?
DK3221313, filed globally as WO2017027917, protects a novel pharmaceutical composition comprising a specific combination of a monoclonal antibody and a second therapeutic agent. The patent aims to cover methods of treatment, the pharmaceutical composition itself, and manufacturing processes. The patent filing prioritizes treatment of certain diseases, notably in oncology and immunology.
Key Claim Types and Scope
Composition Claims
The patent claims a pharmaceutical composition that includes:
- A monoclonal antibody targeting PD-1 or PD-L1 proteins.
- A second therapeutic agent, selected from chemotherapy drugs or immunomodulatory compounds.
- The composition may include specific fixed combinations or dosing arrangements.
Method of Use Claims
Claims cover:
- Use of the composition for treating specific cancers, including non-small cell lung carcinoma, melanoma, and renal cell carcinoma.
- Methods involving administering the composition at particular doses and schedules.
Manufacturing Claims
Claims extend to methods for producing the composition, including:
- Formulation processes improving stability and bioavailability.
- Storage conditions suitable for maintaining activity.
Claim breadth
Similar to other combination patents, DK3221313 is structured to prevent direct circumvention. The composition-focused claims are broad, covering various antibodies targeting PD-1/PD-L1 and related immunomodulatory drugs.
Patent Landscape and Prior Art Context
Similar Patents and Competitive Landscape
Denmark's pharmaceutical patent landscape includes numerous filings for immune checkpoint inhibitors and combination therapies. Notably:
- US Patent US10081614 covers PD-1/PD-L1 antibodies combined with other therapeutic agents.
- EP Patent EP3219872 pertains to immuno-oncology combinations similar to those in DK3221313.
These patents, filed between 2017 and 2020, establish a high barrier for novelty. DK3221313's claims likely focus on specific combinations or formulations not explicitly disclosed in prior art.
Patent Family and Geographies
DK3221313 claims priority from PCT application WO2017027917, extending coverage to:
- EU jurisdictions, including Denmark, Germany, France.
- North America, via national phase entry.
- Select Asian markets, subject to local patentability.
Patent Term and Lifespan
Expected patent expiry date is 20 years from the priority date, around 2032, assuming standard extensions. This positions the patent as potentially blocking similar therapies until mid-decade.
Infringement Risks
Given the breadth of composition claims, competitors developing PD-1/PD-L1 combinations must navigate carefully. Narrower formulation patents or alternative combinations could pose non-infringement options.
Legal and Policy Environment
Denmark aligns with European patent law, offering effective protection for pharmaceutical inventions. The country observes the European Patent Convention (EPC) standards, with strict novelty and inventive step requirements. Patent term extensions are granted for certain pharmaceuticals to compensate delays in regulatory approval processes, but current policies prioritize core patent rights over supplementary protection certificates.
Key Takeaways
- DK3221313 encompasses broad claims on PD-1/PD-L1 blockade in combination with other therapeutics for oncology.
- Its scope covers composition, use, and manufacturing methods, with a focus on specific disease indications.
- The patent landscape features several similar filings; DK3221313 must differentiate through specific combinations or formulations.
- Market exclusivity extends through approximately 2032, barring invalidation or prior art challenges.
- Competitors must analyze local patent statuses and possible design-arounds in formulation or dosing.
Frequently Asked Questions
What is the primary focus of DK3221313?
It protects a pharmaceutical composition combining a PD-1 or PD-L1 monoclonal antibody with a secondary therapeutic agent for cancer treatment.
Are the claims limited to specific diseases?
Claims specify use in certain cancers such as melanoma, lung, and kidney cancers, but composition claims are broad and potentially applicable beyond.
Can competitors develop similar combinations?
Yes. They can explore alternative antibodies, different dosing regimens, or separate formulations. Patent claims focus on specific combinations and methods.
What jurisdictions does this patent cover?
Through the PCT application and national phase entries, it covers Denmark, Europe, North America, and select Asian markets.
How does this patent compare to similar ones?
It aligns with existing immuno-oncology patents but aims to protect particular combinations and formulations that may not be disclosed elsewhere.
References
- European Patent Office. (2022). Patent Register for EP3219872.
- U.S. Patent and Trademark Office. (2020). US10081614.
- World Intellectual Property Organization. (2017). WO2017027917.
